Verastem, Inc. · NASDAQ:VSTM
Verastem — Q2 2025 Earnings Presentation
17 slides from Verastem's earnings presentation, Aug 7, 2025
Slide 1: Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers
Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers Q2FY25 Earnings Call | August 7, 2025
Slide 2: Disclaimers
Disclaimers Forward-Looking Statements This presentation includes forward-looking statements about, among other things, Verastem Oncology’s (the “Company”) programs and product candidates, strategy, future plans and prospects, including statements related to the commercialization of AVMAPKI FAKZYNJA
Slide 3: Verastem Agenda and Conference Call Participants
Verastem Agenda and Conference Call Participants Introduction Julissa Viana VP, Corporate Communications, Investor Relations and Patient Advocacy Business Update Dan Paterson President and Chief Executive Officer Commercial Update Matt Ros Chief Operating Officer Mike Crowther Chief Commercial Offic
Slide 4: Business Update
Dan Paterson President & CEO Business Update 4
Slide 5: Executing Against 2025 Strategic Priorities
Executing Against 2025 Strategic Priorities First-ever FDA-approved therapy for the Commercial product and pipeline are treatment of KRAS-mutated recurrent low- well-positioned to deliver long-term grade serous ovarian cancer (LGSOC) shareholder value Product approved May 8, 2025 Strategic Prioritie
Slide 6: Strong Start to Commercial Launch of AVMAPKI FAKZYNJA CO-PACK
Strong Start to Commercial Launch of AVMAPKI FAKZYNJA CO-PACK Achieved net product revenue of FDA Approval Nearly Two Months Ahead of PDUFA $2.1 million RAS/MAPK Pathway Directed MOA In the first six weeks • AVMAPKI offers dual inhibition of RAF and MEK on the market • FAKZYNJA mediates drug resista
Slide 7: Commercial Update
Matt Ros COO Commercial Update
Slide 8: Laser-Focused on Three Strategic Imperatives to Drive a Successful Commercial Launch
Laser-Focused on Three Strategic Imperatives to Drive a Successful Commercial Launch Effectively reach Top 100 commercial healthcare all healthcare organizations contribute ~50% of providers patient claims1 HCPs Patients progress through other Engage and therapies, and many will be ready for a suppo
Slide 9: Encouraging Launch Momentum Reinforces Strategic Imperatives to Drive Success
Encouraging Launch Momentum Reinforces Strategic Imperatives to Drive Success ✓ First-ever approved treatment specifically Achieved net product revenue of for people living with KRAS-mutated recurrent LGSOC nearly two months in $2.1 million advance of PDUFA in the first six weeks ✓ Urgent, unmet pat
Slide 10: Launch Dynamics
Mike Crowther CCO Launch Dynamics
Slide 11: The First and Only FDA-Approved Treatment Specifically for KRAS-mutated Recurrent LGSOC
The First and Only FDA-Approved Treatment Specifically for KRAS-mutated Recurrent LGSOC Building a strong foundation to support future prescription volume ✓ Prescriptions coming from a mix of academic and community physicians ✓ Seeing both repeat prescriptions and refills ✓ Payer mix is a combinatio
Slide 12: Q2 Financial Update
Dan Calkins CFO Q2 Financial Update 12
Slide 13: Financial Highlights
Financial Highlights Q2FY25 Q2FY24 ($s in thousands) ($s in thousands) Net product revenue $2,137 $0 Total operating expenses $45,901 $28,277 Cost of sales $446 $0 R&D expenses $24,786 $18,062 SG&A expenses $20,669 $10,215 Net loss (Non-GAAP) $41,390 $16,489 $164 million in cash, cash equivalents, a
Slide 14: Closing Remarks
Dan Paterson President & CEO Closing Remarks
Slide 15: Delivering on the Key R&D Milestones Set for 2025
Delivering on the Key R&D Milestones Set for 2025 Maximize the synergistic potential of avutometinib + defactinib in other advanced solid tumors RAMP 205: Avutometinib + Defactinib + ✓ Reported updated data from the ongoing RAMP 205 trial and SOC Chemotherapy in 1L mPDAC selected dose level 1 cohort
Slide 16: Achieved All Key Milestones in 1H25, On Track To Deliver in 2H25
Achieved All Key Milestones in 1H25, On Track To Deliver in 2H25 VS-7375-101 RAMP 301 PRODUCT LAUNCH Expect to report preliminary update Complete planned • Effectively reach HCPs on Phase 1 monotherapy dose enrollment in the Phase 3 • Engage with patients escalation in Q4 2025. Initiate various conf
Slide 17: Q&A
Q&A / VERASTEM ONCOLOGY